Abbreviations used:AE (Adverse experience), C-CASA (Columbia Classification Algorithm of Suicide Assessment), FDA (US Food and Drug Administration), MRL (Merck Research Laboratories), PSRAE (Possibly suicidality-related adverse event), SCC (Suicide Classification Center)
- Early communication about an ongoing safety review of montelukast (SINGULAIR).(Available at)http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm095019.htm(Accessed August 10, 2009)Date: March 27, 2008
- Update of safety review: follow-up to the March 27, 2008, communication about the ongoing safety review of montelukast (Singulair).(January 13, 2009. Available at)http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm079523.htm(Accessed August 10, 2009)Date: January 13, 2009
- Updated information on leukotriene inhibitors: montelukast (marketed as Singulair), zafirlukast (marketed as Accolate), and zileuton (marketed as Zyflo and Zyflo CR).(June 12, 2009. Available at)http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm165489.htm(Accessed August 10, 2009)Date: June 12, 2009
- Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA's pediatric suicidal risk analysis of antidepressants.Am J Psychiatry. 2007; 164: 1035-1043
Psychopharmacologic Drugs Advisory Committee. Available at: http://www.fda.gov/ohrms/dockets/ac/cder04.html#PsychopharmacologicDrugs. Accessed August 10, 2009.
US Food and Drug Advisory Committee FDA briefing document: Zimulti™ (rimonabant) tablets, 20 mg. Available at: http://www.fda.gov/OHRMS/DOCKETS/AC/07/briefing/2007-4306b1-00-index.htm. Accessed August 10, 2008.
Suicidal behavior and ideation and antiepileptic drugs. Available at: http://www.fda.gov/cder/drug/infopage/antiepileptics/default.htm. Accessed August 10, 2009.
- Safety and tolerability of montelukast in placebo-controlled pediatric studies and their open-label extensions.Pediatr Pulmonol. 2009; 44: 568-579
- Montelukast and emotional well-being as a marker for depression: results from 3 randomized, double-masked clinical trials.J Allergy Clin Immunol. 2008; 122: 828-829
- Rate of suicide in patients taking montelukast.Phamacotherapy. 2009; 29: 165-166
- Trends in suicide ideation, plans, gestures, and attempts in the United States, 1990-1992 to 2001-2003.JAMA. 2005; 293: 2487-2495
- Suicide and suicidal behavior.Epidemiol Rev. 2008; 30: 133-154
- Web-based Injury Statistics Query and Reporting System (WISQARS [online]) 2005.(National Center for Injury Prevention and Control, CDC (producer). Available at)Accessed August 10, 2009)
- Suicide trend among youths and young adults aged 10-24 years—United States, 1990-2004.MMWR Morb Mortal Wkly Rep. 2007; 56: 905-908
- Cross-national prevalence and risk factors for suicidal ideation, plans and attempts.Br J Psychiatry. 2008; 192: 98-105
- Suicidal ideation and suicide attempts in general medical illnesses.Arch Intern Med. 2000; 160: 1522-1526
- Asthma, suicidal ideation, and suicide attempts: findings from the Baltimore Epidemiologic Catchment Area follow-up.Am J Public Health. 2005; 95: 717-722
- Asthma and suicide ideation among youth in the community.Crisis. 2004; 25: 99-102
- Tree pollen peaks are associated with increased nonviolent suicide in women.Mol Psychiatry. 2005; 10: 232-238
- Mood-worsening with high-pollen-counts and seasonality: a preliminary report.J Affective Disorders. 2007; 101: 269-274
- Seasonality of suicides with and without psychiatric illness in Denmark.J Affect Disord. 2006; 96: 117-121
- Allergy: a risk factor for suicide?.Curr Treat Options Neurol. 2008; 10: 363-376
- Suicidality and montelukast.Expert Opin Drug Saf. 2009; 8: 273-282
- SINGULAIR® (montelukast sodium) prescribing information.Merck & Co, Inc, Whitehouse Station (NJ)2009
The smoking cessation aids varenicline (marketed as Chantix) and bupropion (marketed as Zyban and generics): suicidal ideation and behavior. US Food and Drug Administration Drug Safety Newsletter. Available at: www.fda.gov/downloads/Drugs/DrugSafety/DrugSafetyNewsletter/ucm107318.pdf. Accessed August 10, 2009.
- Increased expression of cysteinyl leukotriene receptor-1 in the brain mediates neuronal damage and astrogliosis after focal cerebral ischemia in rats.Neuroscience. 2006; 140: 969-979
- The orphan receptor GPR17 identified as a new dual uracil nucleotides/cysteinyl-leukotrienes receptor.EMBO J. 2006; 25: 4615-4627
- Leukotrienes.N Engl J Med. 2007; 357: 1841-1854
- 5-Lipoxygenase in the prefrontal cortex of suicide victims.Open Neuropsychopharmacol J. 2008; 1: 1-5
- 5-lipoxygenase (5LOX)-deficient mice express reduced anxiety-like behavior.Restor Neurol Neurosci. 2002; 20: 15-20
- Effects of MK-866, a 5-liopoxygenase activating protein (FLAP) inhibitor, and 5-lipoxygenase deficiency on the forced swimming behavior of mice.Neurosci Lett. 2008; 436: 269-272
- Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI-resistant depression in adolescents (TORDIA) study.Am J Psychiatry. 2009; 166: 418-426
Philip G, van Adelsberg J, Loeys T, Liu N, Wong P, Lai E, et al. Clinical studies of the DP1 antagonist laropiprant in asthma and allergic rhinitis. J Allergy Clin Immunol. In press 2009
The studies referenced in this article were sponsored by Merck & Co, Inc.
Disclosure of potential conflict of interest: All authors are employees of Merck & Co, Inc, and potentially own stock or have stock options in the company.